A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Active Treatment Extension to Assess the Efficacy and Safety of Fosigotifator for the Treatment of Amyotrophic Lateral Sclerosis

Estudio para evaluar la usabilidad de la introducción de soluciones digitales integrales en la práctica clínica y el valor de su uso en la atención médica de los pacientes con esclerosis múltiple

A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension phase

A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early parkinson’s disease

A Double-Blind, Randomized, Placebo and Active Controlled Study to Evaluate the Efficacy and Safety of Once Daily, Extended Release Levetiracetam as Add-on Therapy in Patients with Refractory Partial Onset Epilepsy

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Un estudio multicéntrico de fase 3, aleatorizado, doble ciego, controlado con placebo para investigar la eficacia, seguridad y tolerabilidad de LP352 en el tratamiento de convulsiones en niños y adultos con encefalopatías epilépticas y del desarrollo

Un estudio multicéntrico de fase 3, aleatorizado, doble ciego, controlado con placebo para investigar la eficacia, seguridad y tolerabilidad de LP352 en el tratamiento de convulsiones en niños y adultos con síndrome de Dravet

Estudio para evaluar la usabilidad de la introducción de soluciones digitales integrales en la práctica clínica y el valor de su uso en la atención médica de los pacientes con esclerosis múltiple

A Phase II, Multicentre, Randomized, Double-blind, Placebo-controlled Sequential Cohort Study to Evaluate the Efficacy and Safety of Two Single Doses of IPN10200 for the Treatment of Blepharospasm in Adults

Estudio de fase 2, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de obexelimab, en pacientes con esclerosis múltiple recidiva

A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Adults Diagnosed With Epilepsy

Epidemiology of Dravet and Lennox–Gastaut syndromes in Spain

Estudio de fase 3, de carácter pivotal, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, con un período de extensión abierta, para evaluar la eficacia y la seguridad de rozanolixizumab en participantes adultos con enfermedad asociada a anticuerpos contra la glucoproteína de la mielina del oligodendrocito (MOG) EudraCT 2021-000352-19

A Prospective, Observational Cohort Study to Assess Long-Term Safety in Patients Prescribed Epidyolex® with a Focus on Drug-induced Liver Injury (DILI)

A Phase 3, randomized, double-blind, study evaluating efficacy and safety of riliprubart versus intravenous immunoglobulin (IVIg) in participants with chronic inflammatory demyelinating polyneuropathy. EudraCT: 2023-508338-33

A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis EUDRACT 2023-504359-29

Un estudio de fase 2 controlado con placebo de VHB937 en la esclerosis lateral amiotrófica (ELA) durante 40 semanas seguido de una extensión abierta

Estudio de fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la tolerabilidad del remibrutinib en pacientes con miastenia grave generalizada seguido de una fase de extensión abierta

Un estudio multicéntrico de fase 2/3, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia, Seguridad y tolerabilidad de BHV-7000 como complemento Terapia en sujetos con enfermedad idiopática generalizada Epilepsia con convulsiones tónico-clónicas generalizadas, con extensión de etiqueta abierta. EudraCT: 2023-508812-45-00

A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy. EudraCT: 2023-508811-21-00

Un estudio de fase 1/2a de escalamiento de dosis para evaluar la seguridad, tolerabilidad, farmacocinética y farmacodinámica de aro-dm1 en sujetos con distrofia miotónica tipo 1 que tienen ≥18 a ≤65 años

A 52-Week, Open-Label Extension Study of ACP-204 in Adults with Alzheimer’s Disease Psychosis

Master Protocol for Three, Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled, Efficacy and Safety Studies of ACP-204 in Adults with Alzheimer’s Disease Psychosis EU CT Number: 2023-507325-42-00

Multi-center, Randomized, Double-blind, Parallel-group, Double-dummy, Active-controlled, Comparative Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Versus Fingolimod During 108Weeks of Treatment in Pediatric Participants, 10 to <18 Years Old, with Relapsing-remitting Multiple Sclerosis

Un estudio de grupo paralelo, aleatorizado, doble ciego para comparar Farmacocinética, farmacodinamia, efectos clínicos y seguridad entre ABP 692 y Ocrevus (Ocrelizumab) en sujetos con esclerosis múltiple remitente recurrente.

A phase 2, randomized, observer-blind, placebo-controlled, dose-ranging study of mRNA-1195 intramuscular injection in participants 18 to ≤55 years of age with early MS

A prospective observational study to evaluate the effectiveness and safety profile of cladribine tablets in a real-world cohort of relapsing multiple sclerosis patients older and younger than 50 years

Randomized placebo-controlled, double-blind clinical trial to investigate treatment effects and safety of Ginkgo biloba extract EGb 761® in participants with cognitive impairment associated with post-COVID-19 syndrome

A Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IGM-2644 in Participants with Myasthenia Gravis

A randomized, phase III, open label study to investigate pharmacokinetics, safety, radiological and clinical effects of subcutaneous frexalimab (SAR441344) compared to intravenous frexalimab in adult participants with multiple sclerosis.

An open-label, multi-center, phase 1/2 study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with progressive Multiple Sclerosis (PMS)

Phase III Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s.

A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Ocular Myasthenia Gravis

A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG).

A ProspeCtive  ObseRvatioNal Study of Atogepant Effectiveness in Routine Clinical Practice